Fig. 4

AAT and C inhibited HIV-1 entry in CD4+ T cells. CD4+ T cells were pretreated in the presence or absence of AAT, C, ΔAAT or HIV-1 entry inhibitor enfuvirtide (10⁻³ g/L) and then infected by HIV-1_NL4.3 (HIV-1 Gag-iGFP) or VSV-G-pseudotyped HIV-1 _NL4.3 (VSV-G-pseudotyped HIV-1 Gag-iGFP) without removing the reagents. Next, infected CD4+ T cells were collected to detect GFP on flow cytometer. As the negative control, one group of non-infected CD4+ T cells was also analyzed (Non-infec Ct) (a). The mean fluorescence intensity of each group was also plotted from three in-dependent experiments on three different donors (b). Meanwhile, these CD4+ T cells were also collected to extract whole cell proteins. HIV-1 entry into CD4+ T cells were determined by measuring cytosolic HIV-1 p24 (c). Ct: HIV-1 Gag-iGFP-infected CD4+ T cells without reagent treatment. Pseudo: VSV-G-pseudotyped HIV-1 Gag-iGFP-treated CD4+ T cells without reagent treatment; ENF: enfuvirtide treatment; Non-infec Ct: non-infected CD4+ T cells